| 2014 | | Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial | 최진혁 |
| 2018 | | Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study | 강석윤, 이현우 |
| 2007 | | Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? | 김유찬 |
| 2011 | | Development of thrombotic microangiopathy in a patient with granulomatosis with polyangiitis. | 박세진, 배기수 |
| 2010 | | Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract. | 김세중 |
| 2009 | | Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. | 강석윤, 김장희, 박광주, 신승수, 오영택, 이현우, 정성현, 정재호, 최진혁, 한재호, 황성철 |
| 2012 | | Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study | 이현우 |
| 2008 | | Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology. | 강석윤, 김장희, 박광주, 신승수, 오영택, 이현우, 정성현, 최진혁, 최호, 한재호, 황성철 |
| 2021 | | Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3) | 이현우 |
| 2015 | | Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. | 강석윤 |
| 2025 | | Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-09) | 안미선 |
| 2013 | | Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. | 강석윤 |
| 2015 | | Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). | 강석윤 |
| 2004 | | Therapeutic effects of gemcitabine on cutaneous manifestations in an Adamantiades-Behçet's disease-like mouse model. | 손성향 |
| 2017 | | Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer | 김진홍, 양민재, 유병무, 이현우, 황재철 |
